Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E0SW
|
|||
| Former ID |
DAP000611
|
|||
| Drug Name |
Enoximone
|
|||
| Synonyms |
ENOXIMONE; Perfan; 77671-31-9; Fenoximone; Enoximonum [Latin]; MDL-17043; Enoximona [Spanish]; MDL 17,043; UNII-C7Z4ITI7L7; MDL-17,043; RMI-17043; 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-dihydroimidazol-2-one; C7Z4ITI7L7; 4-Methyl-5-(p-(methylthio)benzoyl)-4-imidazolin-2-one; CHEMBL249856; 2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5-(4-(methylthio)benzoyl)-; NCGC00015400-02; Enoximonum; Enoximona; 1,3-Dihydro-4-methyl-5-[4-methylthiobenzoyl]-2H-imidazol-2-one; DSSTox_RID_80702; DSSTox_CID_25147; DSSTox_GSID_45147; Perfane; Enoximona; E 1279; Perfan (TN); Enoximone (USAN/INN); Enoximone [USAN:BAN:INN]; 1,3-Dihydro-4-methyl-5-(4-methylthiobenzoyl)-2H-imidazol-2-one; FENOXIMONE
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Congestive heart failure [ICD-11: BD10; ICD-10: I50.0; ICD-9: 428] | Approved | [1] | |
| Therapeutic Class |
Cardiotonic Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H12N2O2S
|
|||
| Canonical SMILES |
CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)SC
|
|||
| InChI |
1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16)
|
|||
| InChIKey |
ZJKNESGOIKRXQY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 77671-31-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7979168, 8183256, 11111134, 12012687, 14749775, 17397999, 17404973, 24278408, 34717755, 46505575, 47349356, 49979887, 50106183, 50106184, 53777516, 56320891, 56320892, 56463672, 57313564, 72605057, 80499070, 85231030, 90340640, 92303896, 92720042, 103558877, 104098757, 104302889, 109692969, 117501074, 121361146, 124749693, 124800754, 124880015, 125823798, 126620365, 126668388, 129911380, 134222996, 134337902, 134341085, 135011523, 137128402, 144203688, 144224578, 160967827, 162178954, 163123997, 163564364, 164814650
|
|||
| ChEBI ID |
CHEBI:135010
|
|||
| SuperDrug ATC ID |
C01CE03
|
|||
| SuperDrug CAS ID |
cas=077671319
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 3 (PDE3) | Target Info | Modulator | [2] |
| Phosphodiesterase 3A (PDE3A) | Target Info | Inhibitor | [3] | |
| KEGG Pathway | Purine metabolism | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Morphine addiction | ||||
| Reactome | cGMP effects | |||
| G alpha (s) signalling events | ||||
| WikiPathways | miR-targeted genes in muscle cell - TarBase | |||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 2 | In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9. | |||
| REF 3 | Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.